Wanbang Pharmaceuticals: The information related to the company advancing the innovation of core pipeline drugs, such as the controlled-release tablets of podophyllotoxin and signing new drug cooperation agreements for diseases like ALS, are all false information.

Notice of abnormal fluctuations and risk warnings in the trading of Wanbang Pharmaceuticals stock: The company has recently noticed that there have been reports in the media and stock forums claiming that Wanbang Pharmaceuticals is advancing with the development of the innovative drug Taxol Methacrylate Controlled-Release Tablets and has signed new drug cooperation agreements for progressive supranuclear palsy, etc. This information is deemed to be untrue. The company has not disclosed its performance for the first half of 2026, nor has it issued any performance forecasts.